Kymera Therapeutics Inc (KYMR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.96 is considered Overvalued compared with the five-year average of -14.85. The fair price of Kymera Therapeutics Inc (KYMR) is between 38.91 to 64.84 according to relative valuation method. Compared to the current price of 90.10 USD , Kymera Therapeutics Inc By Overvalued By 38.95%.

Relative Value

Fair Zone

38.91-64.84

Current Price：90.10

38.95%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Kymera Therapeutics Inc (KYMR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 5.52. Compared to its 3-year average P/B ratio of 3.45, the current P/B ratio is approximately 60.06% higher. Relative to its 5-year average P/B ratio of 4.22, the current P/B ratio is about 30.64% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately -3.95%. Compared to its 3-year average FCF yield of -9.08%, the current FCF yield is approximately -56.45% lower. Relative to its 5-year average FCF yield of -7.64%, the current FCF yield is about -48.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KYMR competitors is 184.72, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR.O) exhibits a P/S ratio of 124.96, which is -32.35% above the industry average. Given its robust revenue growth of -61.18%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KYMR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KYMR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KYMR currently overvalued or undervalued?

What is Kymera Therapeutics Inc (KYMR) fair value?

KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Kymera Therapeutics Inc (KYMR) is between 38.91 to 64.84 according to relative valuation method.

How does KYMR's valuation metrics compare to the industry average?

The average P/S ratio for KYMR's competitors is 184.72, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 124.96, which is -32.35% above the industry average. Given its robust revenue growth of -61.18%, this premium appears unsustainable.

What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Mar 02 2026?

As of Mar 02 2026, Kymera Therapeutics Inc (KYMR) has a P/B ratio of 5.52. This indicates that the market values KYMR at 5.52 times its book value.

What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Mar 02 2026?

As of Mar 02 2026, Kymera Therapeutics Inc (KYMR) has a FCF Yield of -3.95%. This means that for every dollar of Kymera Therapeutics Inc's market capitalization, the company generates -3.95 cents in free cash flow.

What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Mar 02 2026?

As of Mar 02 2026, Kymera Therapeutics Inc (KYMR) has a Forward P/E ratio of -19.50. This means the market is willing to pay $-19.50 for every dollar of Kymera Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kymera Therapeutics Inc (KYMR) as of Mar 02 2026?

As of Mar 02 2026, Kymera Therapeutics Inc (KYMR) has a Forward P/S ratio of 124.96. This means the market is valuing KYMR at $124.96 for every dollar of expected revenue over the next 12 months.

KYMR Valuation